KITE-585 is a chimeric antigen receptor T-cell therapy. It targets a protein called B-cell maturation antigen, or BCMA, that is found on the surface of most multiple myeloma tumors. Because the protein is crucial to myeloma cells’ survival and growth, it is a good target for chimeric antigen receptor T-cell treatments, also known as CAR T-cell therapies.
| SparkCures ID | 298 |
|---|---|
| Developed By | Kite, A Gilead Company |
| Generic Name | KITE-585 |
| Treatment Classifications |
|
February 05, 2019